Financial Data and Key Metrics Changes - In Q4 2025, net sales were $285.2 million, an increase of 8.6% year-over-year, primarily driven by volume growth of 9.7% [17][32] - For the full year 2025, net sales reached $1.102 billion, up 13% year-over-year, aligning with guidance [18][33] - Adjusted gross margin for Q4 was 48.4%, compared to 48.1% in the prior year, while full year adjusted gross margin was 46.7%, up 20 basis points year-over-year [18][34] - Adjusted EBITDA for Q4 was $61.2 million, a 16% increase year-over-year, and for the full year, it was $195.7 million, up 21% [18][36] - Net income for Q4 was $33.8 million, compared to $18.1 million in the prior year, and for the full year, it was $139.1 million, up from $46.9 million [35][36] Business Line Data and Key Metrics Changes - The company reported a significant increase in e-commerce, which grew nearly 40% last year and now represents 14% of total business [9][15] - The company expanded its distribution network, ending the year with products in 30,235 stores, with 24% having multiple fridges [19][20] - The company achieved a household penetration of 15.2 million households, up 10% year-over-year, with a total buy rate of approximately $115, up 4% [21][22] Market Data and Key Metrics Changes - The total addressable market for Freshpet has grown to 36 million households, reflecting a continued interest in high-quality pet food [10] - The company increased its market share in the US dog food segment to 4.0% [19] - The company reported broad-based consumption growth across channels, with Nielsen-measured dollars showing 9.4% growth in total US pet retail [32] Company Strategy and Development Direction - The company is focused on building an omni-channel presence, leveraging its brand equity and manufacturing capabilities to meet consumer demands across various channels [11][52] - The company plans to rebalance its media mix to be more diversified and digital-forward, targeting Millennials and Gen Z consumers [13] - The company is investing in new manufacturing technologies to enhance product quality and operational efficiency, aiming for a competitive advantage [11][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 but emphasized the lessons learned that strengthened the company for future growth [6][7] - The company expects net sales growth of 7% to 10% for 2026, with adjusted EBITDA projected between $205 million and $215 million [24][40] - Management expressed optimism about the potential for growth despite macroeconomic headwinds, citing early signs of improvement in household penetration and buying rates [39][63] Other Important Information - The company welcomed new leadership, including a new CFO and SVP of Supply Chain, to support its growth strategy [27] - The company received $95.5 million from the sale of Ollie, a DTC dog food brand, which will enhance its financial position [29][30] Q&A Session Summary Question: Can you elaborate on the implied uptick in EBITDA margins for 2027? - Management indicated multiple pathways to achieving 20%+ EBITDA margins, including improvements in gross margin and operational efficiencies [44][46] Question: What insights were gained from the investment in Ollie? - The investment provided valuable insights into the DTC market, leading to a focus on building an omni-channel business [50][51] Question: What are the key drivers for consumption growth in 2026? - Management ranked effective advertising, distribution growth, and affordability initiatives as primary drivers for consumption growth [58][61] Question: How is the Fridge Island expansion progressing? - The company is in the test phase with Fridge Islands, which provide increased capacity and assortment, enhancing brand visibility [66][68] Question: What are the expectations for volume growth versus sales growth in 2026? - Management anticipates that volume growth will exceed sales growth due to affordability initiatives and improved entry-level price points [71][73]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [6][12] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% compared to the prior year, and total sales for Auvelity reached $507.1 million, representing a 74% year-over-year increase [12][13] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [16] - Net loss for the full year was $183.2 million, or $3.68 per share, compared to a net loss of $287.2 million, or $5.99 per share for 2024 [17] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth in prescriptions [6][19] - Sunosi generated net product revenue of $36.7 million for Q4, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [13] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [13] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [19] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [20] - Symbravo's overall payer coverage is approximately 52% at the start of the year [22] Company Strategy and Development Direction - The company is advancing a broad CNS pipeline with 5 novel product candidates across 9 high-impact indications [6] - Plans to conduct two Phase 3 trials in ADHD, one in children and one in adolescents, are on track for initiation in the first half of the year [9] - The company aims to expand its sales force to approximately 600 representatives to support growth in MDD and potential launch in Alzheimer's disease agitation [21][59] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver new treatment options for patients living with CNS disorders, supported by a scalable commercial platform [6][11] - The company anticipates that its current cash balance is sufficient to fund operations into cash flow positivity based on the current operating plan [17] - Management is optimistic about the potential impact of the upcoming launch for Alzheimer's disease agitation, with preparations underway [69] Other Important Information - The company has made significant progress with its NDA package for AXS-12 in narcolepsy and expects to submit that imminently [8] - The acquisition of AZD7325, a novel oral GABA A alpha-2/3 receptor positive allosteric modulator, is planned for evaluation in epilepsy [10] Q&A Session Summary Question: Implications of the new FDA publication on the one trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA [28] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the focus is currently on preparing for Phase II readiness [33] Question: Coverage evolution for Auvelity post-ADA label approval - Existing coverage should generally apply to the new indication, but there may be additional efforts needed for Medicare coverage [36] Question: Growth drivers for Sunosi - Growth is driven by both volume and improved access across OSA and narcolepsy markets [44] Question: Sales force expansion rationale - The expansion aims to accelerate growth in MDD and prepare for potential Alzheimer's agitation indication [59] Question: Coverage evolution for Symbravo - The secured contract with a third large GPO allows for active negotiation with payers, with optimism for increased coverage [63]

Freshpet (NasdaqGM:FRPT) Q4 2025 Earnings call February 23, 2026 08:00 AM ET Company ParticipantsBilly Cyr - CEOJohn O'Connor - CFONicki Baty - COORachel Ulsh - VP in Investor Relations and Corporate CommunicationsConference Call ParticipantsBrian Holland - Senior Research AnalystJon Andersen - Research AnalystMichael Lavery - Senior Research AnalystPeter Benedict - Senior Research AnalystPeter Galbo - Senior Equity Research AnalystRobert Moskow - Senior Food & Beverages Research AnalystRupesh Parikh - Seni ...

Axsome Therapeutics (NasdaqGM:AXSM) Q4 2025 Earnings call February 23, 2026 08:00 AM ET Company ParticipantsAndrew Tsai - Managing DirectorAri Maizel - Chief Commercial OfficerAshley Dong - Director of Investor RelationsDavid Hong - Senior Portfolio ManagerGraig Suvannavejh - Managing DirectorHerriot Tabuteau - CEOMark Jacobson - COOMatthew Harrison - Equity Research AssociateNick Pizzie - CFOPete Stavropoulos - Director of Biotech Equity ResearchSean Laaman - Executive DirectorConference Call ParticipantsA ...

MoonLake Immunotherapeutics (NasdaqCM:MLTX) 2026 Investor Day February 23, 2026 08:00 AM ET Company ParticipantsJorge Santos da Silva - CEOJulian Harrison - Managing DirectorKristian Reich - Co-Founder and CSOMatthias Bodenstedt - CFOYun Zhong - SVP of Equity ResearchConference Call ParticipantsBrian Abrahams - Biotechnology Analyst and Global Sector Head of Healthcare ResearchKaveri Pohlman - Managing Director and Senior Equity Research AnalystPrakhar Agarwal - Senior Biotech AnalystThom Smith - Senior Man ...

RESULTS 4Q25 Telefônica Brasil S.A. Investor Relations February 23rd, 2026 This presentation may contain forward -looking statements concerning prospects and objectives regarding the capture of synergies, growth of the subscriber base, a breakdown of the various services to be offered and their respective results Our actual results may differ materially from those contained in such forward - looking statements, due to a variety of factors, including Brazilian political and economic factors, the development ...

Financial Data and Key Metrics Changes - In Q4 2025, net sales were $285.2 million, an increase of 8.6% year-over-year, primarily driven by volume growth of 9.7% [17][31] - For the full year 2025, net sales reached $1.102 billion, up 13% year-over-year, with volume contributing 12% growth [18][33] - Adjusted gross margin for Q4 was 48.4%, compared to 48.1% in the prior year, while full year adjusted gross margin was 46.7%, up 20 basis points year-over-year [18][34] - Adjusted EBITDA for Q4 was $61.2 million, a 16% increase year-over-year, and for the full year, it was $195.7 million, up 21% [18][36] - The company ended the year with cash on hand of $278 million and was free cash flow positive [37] Business Line Data and Key Metrics Changes - The e-commerce business grew nearly 40% last year, now accounting for 14% of total business [8][14] - The company expanded its distribution network significantly, with products now in 30,235 stores, 24% of which have multiple fridges [19][20] - The company achieved its best year in over a decade for new store growth, largely driven by club expansion [13][19] Market Data and Key Metrics Changes - The total addressable market for Freshpet has grown to 36 million households, up from 33 million [9] - The company has increased its market share in the US dog food category to 4.0% [19] Company Strategy and Development Direction - The company is focusing on building an omni-channel presence, leveraging its brand equity and manufacturing capabilities to meet consumer demands across various channels [10][51] - Freshpet aims to enhance its competitive advantages through investments in new manufacturing technologies and expanding its fridge network [10][16] - The company plans to rebalance its media mix to be more diversified and digital-forward, targeting Millennials and Gen Z consumers [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 but emphasized the lessons learned that have strengthened the company for future growth [5] - The company expects net sales growth of 7% to 10% for 2026, with adjusted EBITDA projected between $205 million and $215 million [23][40] - Management remains optimistic about the growth potential despite macroeconomic headwinds, citing early signs of improvement in household penetration and buying rates [64] Other Important Information - The company received $95.5 million from the sale of Ollie, a DTC dog food brand, which has strengthened its financial position [29] - Freshpet is evaluating its capital allocation strategy to accelerate growth and improve margins [29] Q&A Session Summary Question: Can you elaborate on the implied uptick in EBITDA margins for 2027? - Management indicated multiple pathways to achieve 2027 EBITDA margin targets, including improvements in gross margin and net sales growth [44][45] Question: What insights were gained from the investment in Ollie? - The investment provided valuable insights into the DTC market, leading to a focus on building an omni-channel business [49][50] Question: What are the key drivers for consumption growth in 2026? - Management ranked advertising effectiveness, distribution growth, and affordability initiatives as primary drivers for consumption growth [58][61]

Fourth Quarter 2025 Earnings Results February 23, 2026 Safe Harbor Certain information in this presentation consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [4][11] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% compared to the prior year, and total sales for Auvelity reached $507.1 million for the full year, representing a 74% year-over-year increase [12][15] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [15] - Net loss for the full year of 2025 was $183.2 million, or $3.68 per share, compared to a net loss of $287.2 million, or $5.99 per share for 2024 [16] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth contributing to overall revenue [4] - Sunosi generated net product revenue of $36.7 million for Q4, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [12] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [12] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [18] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [19] - Symbravo's overall payer coverage is approximately 52% at the start of the year, with 49% in commercial and 57% in government channels [21] Company Strategy and Development Direction - The company is advancing a broad CNS pipeline with 5 novel product candidates across 9 high-impact indications, including a planned phase 2/3 trial of AXS-05 in smoking cessation [5][6] - AXS-12's NDA submission for narcolepsy is expected imminently, with significant progress made following positive FDA pre-NDA meeting minutes [6] - The company plans to expand its sales force to approximately 600 representatives to support growth in MDD and potential Alzheimer's disease agitation [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver upon vast opportunities for the growing portfolio of CNS medicines, supported by a scalable commercial platform [4][18] - The company anticipates continued momentum in its commercial business and expects to generate significant value through disciplined investment and performance across its CNS portfolios [104] Other Important Information - The company ended the year with $323 million in cash and cash equivalents, compared to $315 million at the end of 2024, indicating sufficient funds to support operations into cash flow positivity [17] - Gross and net discounts for Auvelity and Sunosi are expected to increase due to typical Q1 dynamics, with Symbravo's gross net discount remaining elevated during the launch phase [13] Q&A Session Summary Question: Implications of the new FDA publication on the one trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA, indicating potential for supportive evidence in ongoing studies [26][27] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the company is closely assessing different types of epilepsy for potential clinical success [31][33] Question: Auvelity payer coverage evolution post-ADA label addition - Existing coverage is expected to apply to the new indication, with efforts ongoing to ensure sufficient coverage and utilization management [35][36] Question: Initial launch cadence for Alzheimer's agitation - The company is preparing for a launch within a quarter post-approval, with metrics to be shared regarding script percentages from the ADA space [39][69] Question: Growth drivers for Sunosi - Growth is driven by both volume and improved access, with steady performance in both OSA and narcolepsy markets [44] Question: DTC campaign progress for Auvelity - The national TV campaign launched in late 2025 has generated positive impacts on new patient starts, with ongoing optimization of media spend [46][48] Question: Coverage expectations for Auvelity at steady state - The goal is to secure access for as many patients as possible, with steady progress in increasing covered lives anticipated [50][52] Question: AXS-12 opportunity in narcolepsy - AXS-12 offers compelling treatment options for patients, with strong data in cataplexy and potential benefits in excessive daytime sleepiness [72][74]

U.S. Global Investors October 31, 2025 - December 31, 2025 Second Quarter 2026 Results Webcast WWW.USFUNDS.COM Forward-Looking Statements Frank Holmes CEO and Clo Lisa Callicotte CFO Holly Schoenfeldt Director of Marketing Today's Presenters WWW.USFUNDS.COM & SEAETF vative Investment Manager: During this webcast we may make forward-looking statements about our relative business outlook. Any forward- looking statements and all other statements made during this webcast that don't pertain to historical facts a ...